A groundbreaking study published in JACC, the flagship journal of the American College of Cardiology, has revealed that Baduanjin, a…
Read More
Tirzepatide Confirmed as Best-in-Class Obesity Therapy Following Landmark SURMOUNT-MAINTAIN Trial Results
Findings from the pivotal Phase III SURMOUNT-MAINTAIN trial, presented at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye,…
Read More
EClinical Solutions study models 241% ROI from AI-powered clinical trial data platform
The pharmaceutical industry, perpetually challenged by the immense costs, protracted timelines, and inherent complexities of bringing new therapies to market,…
Read More
Ancient Chinese Exercise Practice Baduanjin Found as Effective as Brisk Walking in Reducing Blood Pressure According to New Clinical Trial
A groundbreaking study published in the Journal of the American College of Cardiology (JACC), the flagship publication of the American…
Read More
Paradigm Health eSource Casebook Revolutionizes Clinical Trial Data Management, Addressing Industry-Wide Challenges
The landscape of clinical trials is undergoing a significant transformation, driven by increasingly complex protocols and the escalating demands placed…
Read More
EClinical Solutions study models 241% ROI from AI-powered clinical trial data platform
The pharmaceutical industry, perpetually grappling with the escalating costs and protracted timelines of drug development, is witnessing a significant paradigm…
Read More
Lilly’s triple agonist achieves 16.8% weight loss in phase 3 trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
The Staggering Cost of Fragmented Clinical Trial Management: A Deep Dive into Inefficiencies and the Promise of Unified Platforms
The global clinical trials market, a critical engine for medical advancement, is currently grappling with pervasive inefficiencies stemming from the…
Read More
Eli Lilly’s Triple Agonist Achieves 16.8% Weight Loss in Phase 3 Trial
Eli Lilly and Company today announced groundbreaking results from a Phase 3 clinical trial for its investigational triple agonist, retatrutide,…
Read More
Harnessing Site Performance for Superior Cardiometabolic Clinical Trial Outcomes
Clinical trials in the highly complex and rapidly evolving field of cardiometabolic disease face a critical juncture: their success or…
Read More
